AR053596A1 - Forma polimorfa ii de tanaproget - Google Patents
Forma polimorfa ii de tanaprogetInfo
- Publication number
- AR053596A1 AR053596A1 ARP060101668A ARP060101668A AR053596A1 AR 053596 A1 AR053596 A1 AR 053596A1 AR P060101668 A ARP060101668 A AR P060101668A AR P060101668 A ARP060101668 A AR P060101668A AR 053596 A1 AR053596 A1 AR 053596A1
- Authority
- AR
- Argentina
- Prior art keywords
- degree
- tanaproget
- polymorph
- lacks
- tanaproget polymorph
- Prior art date
Links
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 title abstract 6
- 229950001471 tanaproget Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 201000010260 leiomyoma Diseases 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 230000002632 myometrial effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67573705P | 2005-04-28 | 2005-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053596A1 true AR053596A1 (es) | 2007-05-09 |
Family
ID=36954854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101668A AR053596A1 (es) | 2005-04-28 | 2006-04-26 | Forma polimorfa ii de tanaproget |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7759341B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1874763A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008539258A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101166736B (cg-RX-API-DMAC7.html) |
| AR (1) | AR053596A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006241125B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0610433A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2603807A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007013469A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200716621A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006116526A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004287875B2 (en) | 2003-11-05 | 2011-06-02 | Bausch + Lomb Ireland Limited | Modulators of cellular adhesion |
| US7767668B2 (en) * | 2005-04-28 | 2010-08-03 | Wyeth Llc | Micronized tanaproget, compositions, and methods of preparing the same |
| MX2007013469A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| WO2006116596A2 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compostions containing same |
| BRPI0610438A2 (pt) | 2005-04-28 | 2012-10-23 | Wyeth Corp | composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição |
| MX2007015571A (es) | 2005-06-09 | 2008-03-06 | Wyeth Corp | Composiciones de tanaproget que contienen etinilestradiol. |
| US20090170823A1 (en) * | 2007-12-20 | 2009-07-02 | Duramed Pharmaceuticals, Inc. | Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception |
| US20110237605A1 (en) * | 2010-03-26 | 2011-09-29 | Eric Phillips | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative |
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| EP2877465A4 (en) | 2012-07-25 | 2016-05-11 | Sarcode Bioscience Inc | LFA-1 HEMMER AND POLYMORPH THEREOF |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100732692B1 (ko) * | 1999-05-04 | 2007-06-27 | 와이어쓰 | 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체 |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| EP1531824A4 (en) * | 2002-06-25 | 2005-09-21 | Wyeth Corp | CYCLOTHIOCARBAMATE DERIVATIVES AS PR-MODULATORS AND THEIR USE IN THE TREATMENT OF SKIN DISEASES |
| AU2003247608A1 (en) * | 2002-06-25 | 2004-01-06 | Wyeth | Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions |
| US8399013B2 (en) * | 2003-06-26 | 2013-03-19 | Poly-Med, Inc. | Partially absorbable fiber-reinforced composites for controlled drug delivery |
| BRPI0510260A (pt) | 2004-04-27 | 2007-10-23 | Wyeth Corp | método para purificar um composto, e, kit farmacêutico |
| PA8631101A1 (es) | 2004-04-27 | 2006-09-08 | Wyeth Corp | Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos |
| AU2005272854B2 (en) * | 2004-08-13 | 2012-04-26 | Wyeth | Tanaproget derivatives, metabolites, and uses thereof |
| BRPI0610438A2 (pt) | 2005-04-28 | 2012-10-23 | Wyeth Corp | composição farmacêutica, cápsula, conjunto farmacêutico, e, processo para preparar uma composição |
| ES2431324T3 (es) | 2005-04-28 | 2013-11-26 | Wyeth Llc | Forma purificada de tanaproget |
| WO2006116596A2 (en) | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compostions containing same |
| US7767668B2 (en) | 2005-04-28 | 2010-08-03 | Wyeth Llc | Micronized tanaproget, compositions, and methods of preparing the same |
| MX2007013469A (es) | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| MX2007015571A (es) | 2005-06-09 | 2008-03-06 | Wyeth Corp | Composiciones de tanaproget que contienen etinilestradiol. |
-
2006
- 2006-04-25 MX MX2007013469A patent/MX2007013469A/es active IP Right Grant
- 2006-04-25 CN CN2006800142218A patent/CN101166736B/zh not_active Expired - Fee Related
- 2006-04-25 BR BRPI0610433-9A patent/BRPI0610433A2/pt not_active IP Right Cessation
- 2006-04-26 TW TW095114816A patent/TW200716621A/zh unknown
- 2006-04-26 US US11/412,015 patent/US7759341B2/en not_active Expired - Fee Related
- 2006-04-26 AR ARP060101668A patent/AR053596A1/es not_active Application Discontinuation
- 2006-04-26 JP JP2008509091A patent/JP2008539258A/ja active Pending
- 2006-04-26 EP EP06751521A patent/EP1874763A2/en not_active Withdrawn
- 2006-04-26 AU AU2006241125A patent/AU2006241125B2/en not_active Ceased
- 2006-04-26 CA CA002603807A patent/CA2603807A1/en not_active Abandoned
- 2006-04-26 WO PCT/US2006/015852 patent/WO2006116526A2/en not_active Ceased
-
2010
- 2010-06-03 US US12/792,978 patent/US7968709B2/en not_active Expired - Fee Related
-
2011
- 2011-05-12 US US13/106,494 patent/US8114869B2/en not_active Expired - Fee Related
-
2012
- 2012-01-10 US US13/347,080 patent/US20120115858A1/en not_active Abandoned
-
2013
- 2013-11-25 JP JP2013242731A patent/JP2014088385A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014088385A (ja) | 2014-05-15 |
| US8114869B2 (en) | 2012-02-14 |
| WO2006116526A8 (en) | 2007-08-16 |
| US7968709B2 (en) | 2011-06-28 |
| AU2006241125B2 (en) | 2012-07-05 |
| US7759341B2 (en) | 2010-07-20 |
| WO2006116526A3 (en) | 2007-06-28 |
| CN101166736A (zh) | 2008-04-23 |
| US20060247235A1 (en) | 2006-11-02 |
| JP2008539258A (ja) | 2008-11-13 |
| US20100267715A1 (en) | 2010-10-21 |
| BRPI0610433A2 (pt) | 2010-11-23 |
| EP1874763A2 (en) | 2008-01-09 |
| US20120115858A1 (en) | 2012-05-10 |
| TW200716621A (en) | 2007-05-01 |
| WO2006116526A2 (en) | 2006-11-02 |
| US20110212953A1 (en) | 2011-09-01 |
| AU2006241125A1 (en) | 2006-11-02 |
| CN101166736B (zh) | 2013-02-06 |
| CA2603807A1 (en) | 2006-11-02 |
| MX2007013469A (es) | 2008-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200716621A (en) | Polymorph form II of tanaproget | |
| CY1110017T1 (el) | Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην | |
| AR056328A1 (es) | TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN | |
| MXPA03011985A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores. | |
| CN103080080B (zh) | 6,7-二氢-5h-苯并[7]轮烯衍生物、其制备方法、包含其的药物制剂以及其用于制备药物的用途 | |
| CY1106610T1 (el) | Μεθοδος για την προληψη ή την θεραπευτικη αντιμετωπιση καλοηθων γυναικολογικων διαταραχων | |
| CO4810234A1 (es) | Vacunas para el tratamiento de virus papiloma humano | |
| JP2008539258A5 (cg-RX-API-DMAC7.html) | ||
| DK1175398T3 (da) | Indolinderivater som progesteronantagonister | |
| TW200731969A (en) | Use of progesterone receptor modulators | |
| RU2016119135A (ru) | Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения | |
| ATE515493T1 (de) | Mercaptophenylnaphthylmethan-derivate und deren herstellung | |
| DK1874278T3 (da) | Sammensætninger indeholdende mikroniseret tanaproget | |
| NZ515353A (en) | Cyclothiocarbamate derivatives as progesterone receptor modulators | |
| CR9598A (es) | Moduladores no esteroides de receptor de progesterona | |
| MX2009009515A (es) | Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona. | |
| CN103421057A (zh) | 康普瑞汀氨基糖缀合物、其制法及其医药用途 | |
| ES2128635T3 (es) | Procedimiento para la obtencion de sulfanos de 2-cloro-6-nitrofenil-alquilo, y nuevos sulfanos de 2-cloro-6-nitrofenilalquilo. | |
| CY1109919T1 (el) | Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης | |
| ECSP056180A (es) | Alquil-estra-1,3,5(10)-trienos 8beta-vinil-11beta-(omega-sustituidos) | |
| ATE263164T1 (de) | Bentzothiophene | |
| AR053595A1 (es) | Forma purificada de tanaproget | |
| PA8772001A1 (es) | "SÍNTESIS Y CARACTERIZACIÓN DE LLA FORMA III POLIMÓRFICA DE 4-(-2-(4,4-DIMETIL-2-OXOOXAZOLIDIN-3i)BENZONITRILO" | |
| KR20130083921A (ko) | 항암 활성을 갖는 벤즈아미드 유도체 및 이의 제조 방법 및 용도 | |
| AR036976A1 (es) | Uso de derivados de acidos 4-biarilbutiricos sustituidos para fabricar medicamentos para el tratamiento de enfermedades cerebrales, sales de los mismos, y composicion farmaceutica que los comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |